There is one clinical trial.
This is phase II study to assess the efficacy of NestaCell® (mesenchymal stem cell) to treat severe COVID-19 pneumonia.
Description: Ordinal scale (WHO ordinal scale that measures illness severity over time)Measure: Change in Clinical Condition Time: 10 days
Description: Evaluation of Pneumonia changeMeasure: Rate of mortality within 10-days Time: 10 days
Description: Evaluation of Pneumonia changeMeasure: Change of Clinical symptoms - respiratory rate Time: 10 days
Description: oxygen saturationMeasure: Hypoxia Time: 10 days
Description: oxygen saturationMeasure: PaO2 / FiO2 ratio Time: 10 days
Description: Marker of Immunological functionMeasure: CD4+ and CD8+ T cell count Time: Days 1, 2, 4, 6 and 8.
Description: PaO2 / FiO2 ratioMeasure: Changes of blood oxygen Time: 10 days
Description: Number of participants with treatment-related adverse eventsMeasure: Side effects in the treatment group Time: 10 days
Description: Complete blood count, ALT, AST, GGT, CK, CKmB and creatinineMeasure: Complete blood count, cardiac, hepatic and renal profiles; Time: Days 1, 2, 4, 6 and 8.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports